Manufacturer of Human Induced Pluripotent Stem Cells Achieves Milestone GMP Certification to Manufacture Cord Blood-derived iPSCs

Manufacturer of human induced pluripotent stem cells, RheinCell Therapeutics, announced it has received Good Manufacturing Practice (GMP) certification and Manufacturing Authorization.

This marks a landmark achievement for RheinCell Therapeutics, which is now among a select few iPSCs manufacturers to have received the critical certification.

The certificate and accompanying manufacturing permit — which were granted following inspection of RheinCell’s manufacturing facilities in September 2020 — confirm that the company’s site follows the GMP principles of the European Union for human medicinal products (2003/94/EC), including requirements for chemical, physical, and biological quality control testing.

“We have reached another milestone in the evolution of our company – one that was borne from the foresight of our manufacturing and quality control teams, and the tremendous work of everyone involved in building an efficient production strategy,” said Jürgen Weisser, CEO of RheinCell. “RheinCell is now one of very few commercial enterprises worldwide that are certified to produce iPSCs – a critical starting material for stem cell-based therapies – in a regulated and GMP-compliant process and environment.”

Heading up the certification efforts was Dr. Katja Aschermann, COO of RheinCell. “At RheinCell, we are proud to implement state-of-the-art, GMP-compliant manufacturing processes to meet the needs of our international customers for ready-to-use, fully characterized clinical-grade iPSC lines,” explained Aschermann.

The GMP certification and Manufacturing Authorization pave the way for the company to deliver fully characterized clinical-grade iPSCs that are derived from human cord blood cells for the development of cell-based therapies. Furthermore, RheinCell has the technology, facilities, know-how and processes to manufacture, expand, differentiate and cryopreserve these cell lines according to specific development needs.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Michael Dabrowski, CEO of Pelago Bioscience "We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.

By using this website you agree to accept Medical Device News Magazine Privacy Policy